QIAGEN’s QIAstat-Dx Test Kit Receives the US FDA’s EUA as the First Syndromic Test to Detect COVID-19

 QIAGEN’s QIAstat-Dx Test Kit Receives the US FDA’s EUA as the First Syndromic Test to Detect COVID-19

QIAGEN, QIAstat-Dx Test Kit, Receives, US, FDA, EUA, First Syndromic Test, Detect, COVID-19

Shots:

  • QIAGEN has received the FDA’s EUA for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test for diagnosing patients infected with the novel COVID-19
  • The syndromic test will be deployed in pandemic and can differentiate the SARS-CoV-2 coronavirus from 21 other serious respiratory infections in patients showing similar symptoms. The kit requires < 1min. for preparing the sample and delivers results in ~1hr
  • The QIAstat-Dx test is a multiplexed nucleic acid test that assesses samples such as nasopharyngeal swabs obtained from individuals suspected of the respiratory tract and is intended to be used in laboratories certified under CLIA to perform moderate and high complexity tests

Click here ­to­ read full press release/ article | Ref: QIAGEN | Image: QIAGEN

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post